FDA Final Guidance on New Dietary Ingredient Notifications Lawsuit

The Food and Drug Administration announced the availability of a final guidance for industry on new dietary ingredient notifications in a Federal Register notice published on October 20, 2026. The guidance addresses frequently asked questions about new dietary ingredient notification submissions. It recommends what identity and safety information manufacturers and distributors should include in a notification.

At a glance

• The action is a notice of availability, published at 91 FR 66336 and ending on page 66337, a two-page document.
• The issuing agencies are the Department of Health and Human Services and the Food and Drug Administration.
• The document carries Docket No. FDA-2025-D-6501 and the Federal Register document number 2026-21453.
• The guidance is titled “New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI: Guidance for Industry.”
• The notice states that the guidance focuses on frequently asked questions about new dietary ingredient notification submissions.

What the October 2026 notice announces

The Food and Drug Administration (FDA) used the notice to announce that a final guidance for industry is available. The agency describes the guidance as focused on frequently asked questions about new dietary ingredient notification (NDIN) submissions. The stated purpose is to help provide recommendations to manufacturers and distributors of new dietary ingredients (NDIs) and of dietary supplements containing an NDI. Those recommendations concern the identity and safety information that should be included in an NDIN.

The Federal Register action is labeled “Notice of availability.” It is not styled as a rule, a proposed rule, or an enforcement action. The document appears in volume 91 of the Federal Register, starting at page 66336 and running through page 66337.

What is established vs. what is alleged

Nothing in this record is an allegation, a court claim, or a disputed factual assertion, so the alleged category does not apply. What is established by the record is narrow and administrative. The FDA published a notice in the Federal Register on October 20, 2026, announcing the availability of a final guidance document bearing the title quoted above. The record also establishes the docket number, the Federal Register citation, the page range, the responsible agencies and the general subject matter of the guidance.

The record does not establish the substantive content of the guidance beyond the agency’s summary. The notice says the guidance addresses frequently asked questions and recommends identity and safety information, but the source documents supplied here do not reproduce the questions, the answers, or any specific recommendation. Any statement about what the guidance requires or recommends beyond that summary is not supported by these documents.

Where the guidance stands procedurally

This is a guidance availability notice, not litigation, so there is no MDL (multidistrict litigation, a procedure that consolidates related federal cases before one judge), no bellwether trial (a test case chosen from a group of similar claims) and no JPML (Judicial Panel on Multidistrict Litigation) involvement in this record. The docket FDA-2025-D-6501 is an FDA docket, and the Regulations.gov entry associated with it lists zero comments and no open comment period. The notice sets no comment deadline and lists no correction or correction-of entry. The announcement date stated in the document is October 20, 2026.

Because the action is an announcement of availability rather than a rulemaking, the notice does not describe a compliance deadline, an effective date or a transition period. The “effective_on” field in the Federal Register metadata is empty.

Key dates

• October 20, 2026: the FDA published the notice of availability in the Federal Register at 91 FR 66336, and the document’s stated date for the announcement is the same day.
• October 20, 2026: the Regulations.gov docket entry for FDA-2025-D-6501-0001 records this date as its comment start date, with no comment end date.
• October 21, 2026: the Federal Register records that the Regulations.gov docket information was checked on this date.
• November 5, 2026: the Federal Register page view counter for the document was last updated on this date.

What this does not establish

The source documents do not contain the text of the guidance itself. They do not describe the specific questions the guidance answers or the specific identity and safety information it recommends. They do not state whether the guidance creates new obligations, restates existing ones, or replaces an earlier version, and they do not identify any prior draft or comment period. They do not address enforcement priorities, inspection practices, product classifications or the status of any particular ingredient or supplement. Nothing in the record reports a lawsuit, a recall, a settlement, a verdict or a regulatory penalty connected to this notice.

Frequently asked questions

What did the FDA publish on October 20, 2026?

The Food and Drug Administration published a Federal Register notice of availability for a final guidance for industry on new dietary ingredient notifications, at 91 FR 66336. The notice announces that the guidance document is available and summarizes its focus as frequently asked questions about NDIN submissions. The document number is 2026-21453 and the docket is FDA-2025-D-6501.

What does the new dietary ingredient notification guidance cover?

According to the notice, the guidance focuses on frequently asked questions about new dietary ingredient notification submissions. It is intended to help provide recommendations to manufacturers and distributors of NDIs and of dietary supplements containing an NDI, regarding the identity and safety information that should be included in an NDIN. The notice does not reproduce the individual questions or recommendations.

Is this notice a rule or a change in requirements?

The Federal Register labels the action a notice of availability, not a rule or proposed rule. The document announces that a final guidance exists and describes its subject matter. It states no effective date, compliance deadline or comment deadline, and the associated Regulations.gov docket lists zero comments.

Is there litigation or a mass tort connected to this guidance?

The source documents show no litigation, MDL, trial date or court proceeding connected to this notice. The record consists of an FDA docket and a Federal Register entry for an administrative announcement. Readers interested in how pharmaceutical and supplement matters move through the courts can review the site’s overview of GLP-1 Ozempic litigation for general context on consolidation.

Where can the guidance itself be read?

The Federal Register entry links to a full-text HTML version, an XML version, a raw text version and a PDF hosted by GovInfo for document 2026-21453. Those links are listed in the record, but the guidance text is not included in the sources used for this article. Readers should consult the linked Federal Register and GovInfo versions directly. Related FDA availability notices, such as the determination for Pepcid RPD famotidine tablets, follow a similar announcement format.

Sources

1. Federal Register (federalregister.gov): “New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI: Guidance for Industry; Availability” (link, accessed 2026-11-05)
2. Federal Register (federalregister.gov): “All Documents” API listing, newest first (link, accessed 2026-11-05)